These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 31226417)

  • 1. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
    Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
    Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
    Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
    Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
    Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
    Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
    PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
    Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
    Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
    Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
    Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
    Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
    Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
    Bellosillo B; Villamor N; Colomer D; Pons G; Montserrat E; Gil J
    Blood; 1999 Oct; 94(8):2836-43. PubMed ID: 10515887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
    Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
    Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
    Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
    Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.
    Podhorecka M; Halicka D; Klimek P; Kowal M; Chocholska S; Dmoszynska A
    Ann Hematol; 2010 Nov; 89(11):1115-24. PubMed ID: 20499237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
    Podhorecka M; Halicka D; Klimek P; Kowal M; Chocholska S; Dmoszynska A
    Ann Hematol; 2011 Feb; 90(2):173-83. PubMed ID: 20714724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
    Faria JR; Yamamoto M; Faria RM; Kerbauy J; Oliveira JS
    Braz J Med Biol Res; 2006 Mar; 39(3):327-33. PubMed ID: 16501812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.
    Melarangi T; Zhuang J; Lin K; Rockliffe N; Bosanquet AG; Oates M; Slupsky JR; Pettitt AR
    Cell Death Dis; 2012 Aug; 3(8):e372. PubMed ID: 22898870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
    Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
    Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
    Qiu L; Liu J; Wang Z; Hu W; Huang Q; Zhou Y
    Oncol Rep; 2015 Sep; 34(3):1239-48. PubMed ID: 26165829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.